Aztreonam-d<sub>6</sub>

Aztreonam-d6

CAT N°: 28799
Price:

548.00 465.80

Aztreonam-d6 is intended for use as an internal standard for the quantification of aztreonam (Item No. 19784) by GC- or LC-MS. Aztreonam is a synthetic ?-lactam antibiotic of the monobactam class.{31705} It is active against clinical isolates of E. coli, S. marcescens, P. aeruginosa, Klebsiella species, Proteus species, and Enterobacter species (MICs = S. pneumoniae, B. fragilis, and S. faecalis (MICs = >100 µg/ml for all). It interferes with peptidoglycan synthesis in the bacterial cell wall of the Gram-negative bacteria E. coli, P. vulgaris, E. cloacae, K. pneumoniae, and P. aeruginosa by inhibiting penicillin-binding protein 3 (PBP3; IC100 = 0.1 µg/ml for all). It increases survival in mice with systemic Gram-negative bacterial infections (ED50s = 0.1-24.7 mg/kg). Formulations containing aztreonam have been used in the treatment of P. aeruginosa infections in individuals with cystic fibrosis.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-(methyl-d3)-propanoic-3,3,3-d3 acid
  • Correlated keywords
    • GCMS LCMS deuterated deuterium anti biotic Escherichia Serratia Pseudomonas Streptococcus Bacteroides PBP CF SQ26,776 SQ26776 26776
  • Product Overview:
    Aztreonam-d6 is intended for use as an internal standard for the quantification of aztreonam (Item No. 19784) by GC- or LC-MS. Aztreonam is a synthetic ?-lactam antibiotic of the monobactam class.{31705} It is active against clinical isolates of E. coli, S. marcescens, P. aeruginosa, Klebsiella species, Proteus species, and Enterobacter species (MICs = S. pneumoniae, B. fragilis, and S. faecalis (MICs = >100 µg/ml for all). It interferes with peptidoglycan synthesis in the bacterial cell wall of the Gram-negative bacteria E. coli, P. vulgaris, E. cloacae, K. pneumoniae, and P. aeruginosa by inhibiting penicillin-binding protein 3 (PBP3; IC100 = 0.1 µg/ml for all). It increases survival in mice with systemic Gram-negative bacterial infections (ED50s = 0.1-24.7 mg/kg). Formulations containing aztreonam have been used in the treatment of P. aeruginosa infections in individuals with cystic fibrosis.

We also advise you